Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.61 |
| ▸ | PARP1 | P09874 | 5/20 | 0.61 |
| ▸ | TNKS | O95271 | 4/20 | 0.59 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29179948 | 0.86 | PKM (0.66) | PKMTNKS2PARP1TNKSQTRT1 | |
| SCHEMBL7530802 | 0.86 | PKM (0.66) | PKMTNKS2PARP1TNKSQTRT1 | |
| SCHEMBL7533742 | 0.84 | PKM (0.72) | PKMTNKS2PARP1TNKSQTRT1 | |
| SCHEMBL18923552 | 0.83 | PKM (0.62) | PKMTNKS2PARP1TNKSQTRT1 | |
| SCHEMBL29499008 | 0.83 | PKM (0.62) | PKMTNKS2PARP1TNKSQTRT1 | |
| SCHEMBL3118169 | 0.82 | PKM (1.00) | PKMTNKS2PARP1TNKSQTRT1 | |
| SCHEMBL894415 | 0.82 | PKM (0.70) | PKMTNKS2PARP1TNKSQTRT1 | |
| SCHEMBL30388114 | 0.82 | PKM (1.00) | PKMTNKS2PARP1TNKSQTRT1 | |
| SCHEMBL29179915 | 0.81 | TNKS2 (0.59) | PKMTNKS2PARP1TNKSQTRT1 | |
| SCHEMBL29179963 | 0.80 | PKM (0.61) | PKMTNKS2PARP1TNKSQTRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62258368-A | — | — | None | — | — | JP | disclosed |
| EP-4069709-B1 | METAL COMPLEXES | UDC IRELAND LTD (IE) | 2025-04-23 | — | — | EP | disclosed |
| US-11337970-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220017474-A1 | Novel Polycyclic Compound | EUTEC NEW MATERIALS TECHNOLOGY (SUZHOU) CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20210290613-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-23 | — | — | US | disclosed |
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-11-12 | — | — | US | disclosed |
| US-9802949-B2 | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-9670194-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670194-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20150307509-A1 | FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-29 | — | — | US | disclosed |
| US-20150299215-A1 | SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| CN-104557738-A | Green synthesis method of 4(3H)-quinazolinone | UNIV HUNAN | 2015-04-29 | — | — | CN | disclosed |
| US-20150087663-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| US-20100267633-A1 | N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-10-21 | — | — | US | disclosed |
| US-20100068211-A1 | USE OF ANTIRESORPTIVE COMPOUNDS TO PREVENT IONIZING RADIATION-INDUCED ACTIVATION OF OSTEOCLASTS AND RESULTING BONE LOSS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-03-18 | — | — | US | disclosed |
| US-20100068211-A1 | USE OF ANTIRESORPTIVE COMPOUNDS TO PREVENT IONIZING RADIATION-INDUCED ACTIVATION OF OSTEOCLASTS AND RESULTING BONE LOSS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-03-18 | — | — | US | disclosed |
| JP-S62258368-A | PRODUCTION OF QUINAZOLIN-4-ONE | AGENCY OF IND SCIENCE & TECHNOL | 1987-11-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087663-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MYD88 | PKM 820/4885TNKS2 485/4885PARP1 632/4885 |
| US-20150299215-A1 | SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF | HAVCR2, SLC10A1, SORD | PKM 1499/4885TNKS2 4062/4885PARP1 4459/4885 |
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | XBP1, RNASE1, ERN1 | PKM 2954/4885TNKS2 2192/4885PARP1 751/4885 |
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | HAVCR2, SLC10A1, SORD | PKM 1879/4885TNKS2 3917/4885PARP1 4324/4885 |
| US-20150307509-A1 | FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CUL4A, GTF3C4, HAVCR2 | PKM 3693/4885TNKS2 3844/4885PARP1 2343/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | PKM 2544/4885TNKS2 3320/4885PARP1 2611/4885 |
| US-11337970-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | PKM 2054/4885TNKS2 356/4885PARP1 832/4885 |
| US-20220017474-A1 | Novel Polycyclic Compound | CUTA, DSG1, UACA | PKM 2706/4885TNKS2 1752/4885PARP1 399/4885 |
| US-20100267633-A1 | N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators | AR, FSHR, SHBG | PKM 1109/4885TNKS2 1609/4885PARP1 1093/4885 |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SLC10A1, HAVCR2, UGT1A3 | PKM 2789/4885TNKS2 3873/4885PARP1 4233/4885 |
| US-20210290613-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | PKM 2054/4885TNKS2 356/4885PARP1 832/4885 |
| US-20100068211-A1 | USE OF ANTIRESORPTIVE COMPOUNDS TO PREVENT IONIZING RADIATION-INDUCED ACTIVATION OF OSTEOCLASTS AND RESULTING BONE LOSS | CTSA, SOST, CTSB | PKM 3828/4885TNKS2 1393/4885PARP1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.